Beneficial Effects of Polydeoxyribonucleotide (PDRN) in an In Vitro Model of Fuchs Endothelial Corneal Dystrophy.
Fuchs endothelial corneal dystrophy
ROS
apoptosis
inflammation
oxidative stress
polydeoxyribonucleotide
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
03 Apr 2022
03 Apr 2022
Historique:
received:
10
03
2022
revised:
31
03
2022
accepted:
01
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Fuchs endothelial corneal dystrophy (FECD) is a bilateral, hereditary syndrome characterized by progressive irreversible injury in the corneal endothelium; it is the most frequent cause for corneal transplantation worldwide. Oxidative stress induces the apoptosis of corneal endothelial cells (CECs), and has a crucial function in FECD pathogenesis. The stimulation of the adenosine A
Identifiants
pubmed: 35455444
pii: ph15040447
doi: 10.3390/ph15040447
pmc: PMC9025871
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hum Mol Genet. 2015 Nov 1;24(21):6066-79
pubmed: 26264576
Annu Rev Vis Sci. 2019 Sep 15;5:151-175
pubmed: 31525145
Ocul Surf. 2010 Oct;8(4):173-84
pubmed: 20964980
Foot Ankle Surg. 2020 Aug;26(6):657-661
pubmed: 31521520
Exp Eye Res. 2018 Sep;174:40-50
pubmed: 29792846
Int J Mol Sci. 2017 Aug 24;18(9):
pubmed: 28837114
Br J Pharmacol. 2018 Feb;175(4):644-655
pubmed: 29178246
J Leukoc Biol. 2001 Nov;70(5):821-9
pubmed: 11698503
Front Pharmacol. 2016 Aug 23;7:273
pubmed: 27601997
Appl Biochem Biotechnol. 2020 Jun;191(2):540-554
pubmed: 31811642
Exp Eye Res. 2014 Oct;127:20-5
pubmed: 24952277
Curr Med Chem. 2018;25(30):3597-3612
pubmed: 29532748
Int J Mol Sci. 2020 Oct 24;21(21):
pubmed: 33114315
Curr Eye Res. 2017 Jan;42(1):47-53
pubmed: 27269503
Histochem Cell Biol. 2015 May;143(5):531-43
pubmed: 25511416
Eur J Ophthalmol. 2004 Jul - Aug 2004;14(4):284-289
pubmed: 28221443
Cell Transplant. 2018 Nov;27(11):1623-1633
pubmed: 30311500
Am J Pathol. 2010 Nov;177(5):2278-89
pubmed: 20847286
Biomedicines. 2020 Jun 17;8(6):
pubmed: 32560286
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
JAMA Ophthalmol. 2018 Aug 1;136(8):886-892
pubmed: 29852040
Oncogene. 2003 Feb 27;22(8):1206-18
pubmed: 12606947
Antioxidants (Basel). 2021 Feb 20;10(2):
pubmed: 33672553
Int Neurourol J. 2021 May;25(Suppl 1):S19-26
pubmed: 34053207
Exp Eye Res. 2021 Jun;207:108574
pubmed: 33848524
Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5829-35
pubmed: 23882692
Biomed Pharmacother. 2021 Jun;138:111538
pubmed: 34311536
Front Pharmacol. 2017 Apr 26;8:224
pubmed: 28491036
Exp Eye Res. 2019 Nov;188:107794
pubmed: 31518569
Neurosci Lett. 2003 Oct 23;350(2):127-31
pubmed: 12972169
Oxid Med Cell Longev. 2016;2016:3164734
pubmed: 26881021
New Microbiol. 2003 Jan;26(1):13-26
pubmed: 12578307
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059361
Arch Ophthalmol. 2001 Nov;119(11):1597-604
pubmed: 11709009
Int Neurourol J. 2020 Nov;24(Suppl 2):88-95
pubmed: 33271005
Biomedicines. 2020 Oct 20;8(10):
pubmed: 33092298
Int Orthop. 2015 Jul;39(7):1329-34
pubmed: 25920599
PLoS One. 2018 May 22;13(5):e0197750
pubmed: 29787599
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3286-3293
pubmed: 29971448
Medicine (Baltimore). 2019 Sep;98(39):e17386
pubmed: 31574892
PLoS One. 2021 Mar 18;16(3):e0248689
pubmed: 33735236
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1196-1207
pubmed: 28245300
Biomed Res Int. 2020 Feb 21;2020:2169083
pubmed: 32149087
Arthritis Res Ther. 2011;13(6):R197
pubmed: 22146575
J Inflamm Res. 2021 Feb 15;14:367-378
pubmed: 33623409
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867310